Life sciences tracker [Archived]
Life sciences tracker [Archived]

The following Life Sciences practice note provides comprehensive and up to date legal information covering:

  • Life sciences tracker [Archived]
  • Legislation
  • Judgments—Patents
  • Supreme Court
  • Court of Appeal
  • High Court
  • IPEC
  • Court of Justice/General Court
  • Judgments—Supplementary protection certificates
  • Court of Appeal
  • More...

ARCHIVED: This Practice Note has been archived and it is not maintained. It contains closed legislative proposals, published judgments and closed consultations that are no longer featured in the current Life sciences tracker—UK and Life sciences tracker—EU because they are not from the current year.

To track the progress of current legislative proposals, relevant cases and consultations related to life sciences, see Practice Notes: Life sciences tracker—UK and Life sciences tracker—EU.

Jump to:

  1. Legislation

  2. Judgments—Patents

  3. Judgments—Supplementary protection certificates

  4. Judgments—Medical devices and medicinal products

  5. Judgments—Access to documents

  6. Judgments—Trade marks

  7. Consultations

For current items on life sciences, see Practice Notes: Life sciences tracker—UK and Life sciences tracker—EU.

For key developments and guidance related to Brexit in the life sciences sector, including the timeline of the relocation of the European Medicines Agency (EMA), see Practice Note: Life sciences—Brexit tracker.


For current legislation, see Practice Notes: Life sciences tracker—UK—Legislation and Life sciences tracker—EU—Legislation.

What's happening?When?Find out more
Regulation amending Regulation (EC) 469/2009 concerning the supplementary protection certificates (SPCs) for medicinal products1 July 2019:
Entry into force
Following a 2017 consultation (see ‘European Commission consultation on SPCs’ in (Consultations—Closed consultations)), in May 2018, the European Commission proposed a targeted adjustment to the SPC regime: the so-called ‘export manufacturing waiver’. In the future, EU-based companies will be entitled to manufacture a generic or biosimilar version of an SPC-protected medicine during

Popular documents